# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

> **NCT02607228** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 31 (actual)

## Conditions studied

- Metastatic Castrate-Resistant Prostate Cancer

## Interventions

- **DRUG:** Alobresib
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT02607228
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-08
- **Primary completion:** 2017-10-25
- **Final completion:** 2019-09-03
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02607228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02607228, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02607228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*